Brainsway Deep TMS Therapy - for Brain Disorder Treatment

About Brainsway Deep TMS Therapy - Providers

Brainsway TMS Therapy - The New Paradigm in Brain Disorder Treatment

Brainsway* introduces a new approach in brain disorder treatment, with a an effective* medication-free solution which can restore wellbeing for patients. Brainsway's Deep TMS therapy (Transcranial Magnetic Stimulation) is a non-invasive technology which can stimulate the brain regions relevant for different brain disorders and bring significant improvement*.

A non-invasive outpatient procedure, Brainsway Deep TMS does not require hospitalization or anesthesia, and entails no memory loss, no systemic side effects* and no indefinite medication intake.

Effective for a Variety of Brain Disorders*

Brainsway Deep TMS therapy has been cleared by the CE* for treatment of the following brain disorders:

  • Alzheimer's disease
  • Autism
  • Bipolar disorder
  • Chronic pain
  • Major depressive disorder
  • Parkinson's disease
  • Posttraumatic stress disorder (PTSD)
  • Schizophrenia (negative symptoms)
  • Smoking cessation
  • OCD
  • Stroke rehabilitation
  • Multiple Sclerosis

Short Sessions that Integrate into the Patient's Routine

Brainsway Deep TMS sessions provide effective results in nearly half the time of traditional TMS sessions for depression (just 20 minutes per session compared to 37 with traditional TMS). Brainsway's Deep TMS is administered over 4-6 weeks. In each session, the patient is comfortably seated in a chair, and a cushioned helmet is gently placed over the head. The helmet generates brief magnetic fields, at a similar amplitude to that used in magnetic resonance imaging (MRI) systems. After each session, patients can return home independently, and immediately resume their daily routine.

Brainsway's advantages over other treatments for depression – click here to learn more.

For references click here

For safety information click here

The Brainsway Deep TMS therapy  is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. K122288


© Brainsway Ltd.® 2014 | All rights reserved. Patients Portal · Brainsway Deep TMS · FDA Clearance · Disclaimer · Privacy Policy · Terms of Use